The drug candidate PL8177 reduced inflammation, protected lung tissue and reduced lung fibrosis in pre-clinical models with symptoms of COVID-19.
List view / Grid view
Filter the results
29 September 2015 | By Victoria White
Preclinical data showed that treatment with PL-3994 significantly reduced cardiac hypertrophy and pro-fibrotic and inflammatory gene activation...